Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Nine companies work for generic Cymbalta
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Dec 3, 2013 04:02:32
Nine Korean pharmaceutical companies are working on their generic versions of Cymbalta that will go off patent in August 2014.

The nine companies include Samjin, Kolmar, Daewoong, Ildong, Hwanin, Korea, Pacific, LG Life Sciences, and Shinpoong. They expect marketing approval of their generic versions before August 2014.

Cymbalta annual sales are about 10 billion won. Its sales rose 66% in 2012 as the antidepressant market expanded.

A pharmaceutical marketer said, “More companies will jump on the bandwagon later as the patent expires next year.”
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com